Celldex Therapeutics, Inc. $CLDX Shares Sold by Simplify Asset Management Inc.

Simplify Asset Management Inc. lowered its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 18.8% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 68,994 shares of the biopharmaceutical company’s stock after selling 16,006 shares during the period. Simplify Asset Management Inc. owned 0.10% of Celldex Therapeutics worth $2,188,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Y Intercept Hong Kong Ltd bought a new stake in Celldex Therapeutics during the first quarter valued at $1,433,000. Assenagon Asset Management S.A. bought a new stake in shares of Celldex Therapeutics during the 1st quarter valued at about $4,648,000. Diversified Trust Co acquired a new stake in Celldex Therapeutics during the first quarter worth about $223,000. Invesco Ltd. lifted its holdings in Celldex Therapeutics by 14.3% in the fourth quarter. Invesco Ltd. now owns 90,144 shares of the biopharmaceutical company’s stock worth $2,448,000 after acquiring an additional 11,258 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its stake in Celldex Therapeutics by 491.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 646,767 shares of the biopharmaceutical company’s stock valued at $17,566,000 after acquiring an additional 537,325 shares during the period.

Wall Street Analyst Weigh In

CLDX has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Monday, April 20th. Barclays upped their target price on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective for the company in a research report on Monday, March 23rd. Finally, UBS Group raised their target price on Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.30.

Celldex Therapeutics Stock Performance

CLDX stock opened at $38.37 on Friday. Celldex Therapeutics, Inc. has a one year low of $19.72 and a one year high of $39.16. The firm has a market capitalization of $3.01 billion, a PE ratio of -9.01 and a beta of 0.90. The firm has a 50-day moving average of $32.40 and a two-hundred day moving average of $29.56.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.80 million. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.